Biomarin Pharmaceutical Inc. (BMRN) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Biomarin Pharmaceutical’s revenue went from $1.1B in fiscal 2016 to $3.2B in fiscal 2025, growth of about 12.5% a year.
Net income in fiscal 2025 was $349M, a net margin of 10.8%; the best year in this period was 2020 with $854M.
Over the twelve months to September 30, 2026, revenue was $3.7B and net income -$19M.
Free cash flow was $725M in fiscal 2025 and positive in 5 of the 10 years shown.
The diluted share count rose 19% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.7B | $3.2B | $2.9B | $2.4B | $2.1B | $1.8B | $1.9B | $1.7B | $1.5B | $1.3B | $1.1B |
| Gross profit | $2.8B | $2.5B | $2.3B | $1.9B | $1.6B | $1.4B | $1.3B | $1.3B | $1.2B | $1.1B | $907M |
| Operating income | $114M | $409M | $484M | $186M | $161M | -$82M | -$43M | -$100M | -$124M | -$15M | -$803M |
| Net income | -$19M | $349M | $427M | $168M | $142M | -$64M | $854M | -$24M | -$77M | -$117M | -$630M |
| EPS (diluted) | $-0.10 | $1.80 | $2.21 | $0.87 | $0.75 | $-0.35 | $4.50 | $-0.13 | $-0.44 | $-0.67 | $-3.81 |
| R&D | — | $922M | $747M | $747M | $650M | $629M | $628M | $715M | $696M | $611M | $662M |
| Revenue growth | — | +12.9% | +18.0% | +15.4% | +13.5% | −0.8% | +9.2% | +14.3% | +13.5% | +17.6% | +25.5% |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $677M | $828M | $573M | $159M | $176M | $305M | $85M | $48M | $20M | -$9M | -$228M |
| Capital spending | -$119M | -$103M | -$85M | -$97M | -$121M | -$96M | -$114M | -$145M | -$145M | -$199M | -$148M |
| Free cash flow | $558M | $725M | $487M | $63M | $55M | $209M | -$29M | -$97M | -$124M | -$208M | -$376M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | — | — | — | — | $0 | $0 | $50M | $0 | $0 | — | — |
| Stock-based pay | $220M | $181M | $202M | $207M | $196M | $197M | $190M | $160M | $149M | $140M | $135M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $1.6B | $1.1B | $1.1B | $1.3B | $1.0B | $1.1B | $754M | $1.1B | $1.4B | $790M |
| Debt | — | $645M | $638M | $1.1B | $1.1B | $1.1B | $1.1B | $922M | $870M | $814M | $661M |
| Equity | — | $6.1B | $5.7B | $5.0B | $4.6B | $4.3B | $4.1B | $3.1B | $3.0B | $2.8B | $2.8B |
| Total assets | — | $7.6B | $7.0B | $6.8B | $6.4B | $6.0B | $5.8B | $4.7B | $4.4B | $4.6B | $4.0B |
| Shares (diluted) | 194M | 197M | 197M | 192M | 189M | 183M | 192M | 179M | 177M | 174M | 166M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 76.0% | 77.7% | 79.7% | 78.0% | 76.0% | 74.5% | 71.8% | 78.9% | 78.9% | 81.6% | 81.2% |
| Operating margin | 3.1% | 12.7% | 17.0% | 7.7% | 7.7% | -4.5% | -2.3% | -5.9% | -8.3% | -1.1% | -71.9% |
| Net margin | -0.5% | 10.8% | 15.0% | 6.9% | 6.8% | -3.5% | 45.9% | -1.4% | -5.2% | -8.9% | -56.4% |
| FCF margin | 15.3% | 22.5% | 17.1% | 2.6% | 2.6% | 11.3% | -1.6% | -5.7% | -8.3% | -15.8% | -33.7% |
| ROIC | — | 4.4% | 6.1% | 2.7% | 2.7% | -1.3% | -0.7% | -2.0% | -1.7% | -0.3% | -17.8% |
| ROE | — | 5.7% | 7.5% | 3.4% | 3.1% | -1.5% | 20.8% | -0.8% | -2.6% | -4.2% | -22.8% |
Frequently asked questions
What is Biomarin Pharmaceutical’s annual revenue?
$3.2B in fiscal 2025 and $3.7B over the twelve months to September 30, 2026.
How much profit does Biomarin Pharmaceutical make?
Net income was $349M in fiscal 2025 (net margin 10.8%).
Is Biomarin Pharmaceutical’s revenue growing?
Yes: revenue rose 12.9% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.